Allogene Therapeutics (ALLO) Accumulated Depreciation & Amortization: 2019-2025
Historic Accumulated Depreciation & Amortization for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $3.1 million.
- Allogene Therapeutics' Accumulated Depreciation & Amortization fell 3.43% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year decrease of 9.72%. This contributed to the annual value of $13.6 million for FY2024, which is 3.95% down from last year.
- As of Q3 2025, Allogene Therapeutics' Accumulated Depreciation & Amortization stood at $3.1 million, which was down 0.29% from $3.1 million recorded in Q2 2025.
- Allogene Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $44.0 million for Q2 2023, and its period low was $3.1 million during Q3 2025.
- For the 3-year period, Allogene Therapeutics' Accumulated Depreciation & Amortization averaged around $10.4 million, with its median value being $3.5 million (2023).
- As far as peak fluctuations go, Allogene Therapeutics' Accumulated Depreciation & Amortization skyrocketed by 101.29% in 2021, and later crashed by 91.72% in 2024.
- Quarterly analysis of 5 years shows Allogene Therapeutics' Accumulated Depreciation & Amortization stood at $23.4 million in 2021, then soared by 57.89% to $36.9 million in 2022, then slumped by 90.57% to $3.5 million in 2023, then declined by 7.04% to $3.2 million in 2024, then dropped by 3.43% to $3.1 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $3.1 million for Q3 2025, versus $3.1 million for Q2 2025 and $3.1 million for Q1 2025.